Session: SUN 807-838-Diabetes - Diagnosis, Complications & Outcomes
Poster Board SUN-826
Methods: In this retrospective study, the association between type 2 DM in Chinese female patients who were diagnosed with cancer and admitted to a hospital was determined. Women were identified through admission data from Chang Gung Memorial Hospital (CGMH) in Linkou, Taiwan between January 2000 and December 2010. The International Classification of Disease-9 (ICD-9) diagnostic codes was used to identify the disease states of patients and the presence of different cancer types in patients with and without type 2 DM was assessed. Patients over 19 years of age were included if the indication for hospital admission was a diagnosis of type 2 DM or a malignancy. A total of 67,660 females with a mean age 62.76 ± 14.48 years were enrolled. These patients were categorized into the following three groups: patients with cancer, but without DM (group A); patients with cancer and DM (group B); and patients with DM, but without cancer (group C). Attributable fractions (AFs) were calculated to evaluate the impact of type 2 DM for mortality in specific cancer. AFs were calculated as [(hazard ratio - 1)/ hazard ratio] X 100.
Results: Of the study subjects, 37,204 (54.98 %) were diagnosed with type 2 DM. as follows: groups A, n=30,456; group B, n=5,992; and group C, n=31,212. Group B patients had a high frequency of pancreas, liver, and renal cancers, and a low frequency of thyroid, breast, and ovarian cancers. Of the 36,448 cancer patients, 2,906 (7.97%) died. The mortality rate of group B (10.45%) was significantly higher than groups A (7.48%; HR = 1.40) and C (3.44%; HR = 3.04). Type 2 DM increased mortality in most cancers. The data showed tope three AFs were thyroid cancer, NPC and urinary tract cancer.
Conclusion: The findings of this study showed that the presence of type 2 DM may influence the development of certain cancer types. The mortality rates of female cancers with type 2 DM are more significantly increased in less aggressive cancer types.
Nothing to Disclose: JDL, JYC, WKC, WYC
*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm
See more of: Abstracts - Orals, Featured Poster Presentations, and Posters